News for Vera Therapeutics, Inc. (VERA)

Summary Protagonist Therapeutics Inc (PTGX) has announced that an abstract detailing the results of their Phase 3 study on Rusfertide for the treatment of polyc

Vera Therapeutics Inc (VERA), a late clinical-stage biotechnology company, announced on April 9, 2025, that its Compensation Committee has granted inducement aw

**media[590880]**

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock

On April 3, 2025, Vera Therapeutics Inc (VERA), a late clinical-stage biotechnology company, announced the completion of full enrollment in its pivotal ORIGIN P

**media[563779]**

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.

On February 27, 2025, Silence Therapeutics PLC (SLNCF) released its 8-K filing detailing its financial results for the full year ending December 31, 2024. The c

Vera Therapeutics Inc (VERA), a late clinical-stage biotechnology company dedicated to developing transformative treatments for serious immunological diseases,

Vera Therapeutics Inc (VERA), a late clinical-stage biotechnology company, has announced significant advancements in its clinical development program for atacic

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S

Transaction Overview On February 7, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring additional shares in Nurix Therapeutics

Vera Therapeutics (VERA) stock falls as Otsuka (OTSKF) updates on its IgA nephropathy therapy sibeprenlimab, which rivals Vera’s (VERA) atacicept. Read more here.

On December 31, 2024, Eversept Partners, LP (Trades, Portfolio) executed a significant reduction in its holdings of Community Health Systems Inc (CYH). The firm

Overview of Avoro Capital Advisors LLC (Trades, Portfolio)'s Recent Transaction On December 31, 2024, Avoro Capital Advisors LLC (Trades, Portfolio) made a sign

Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a recent pullback in the stock. Read more here.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Vera Therapeutics Inc (VERA), a late clinical-stage biotechnology company, announced on January 14, 2025, that its Compensation Committee has granted inducement

BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ( VERA) today announced that on January 8, 2025, the Compensation Committee grante